Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer: A Randomized Controlled Trial

NCT03298074 is registered in ClinicalTrials.gov with Yang Zhijun as lead sponsor.

NCT NCT03298074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03298074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer: A Randomized Controlled Trial
Lead sponsor
Yang Zhijun
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2017
Completion date
April 30, 2019
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer